Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAetna G-POEM GES Coverage & Prior Auth | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0678

    Gastric Pacing / Electrical Stimulation and Gastroesophageal Per Oral Endoscopic Myotomy

    Customize your policy alerts

    Sign up for Aetna Policy 0678 alerts

    Get alerted when Policy 0678 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, investigational determinations, and coding guidance for gastric electrical stimulation/pacing and per-oral endoscopic myotomy (including G-POEM and Zenker POEM) for members with gastroparesis or Zenker diverticulum.

    Policy Summary
    PayerAetna
    PolicyGastric Pacing / Electrical Stimulation and Gastroesophageal Per Oral Endoscopic Myotomy
    Policy CodePolicy 0678
    Change TypeNo material changes
    Effective DateFeb 6, 2004
    Last ReviewSep 25, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization and document refractory gastroparesis with objective delayed gastric emptying and prior failure of conservative therapies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    35+references
    84%pooled clinical response
    12%pooled AE rate
    2023-09-25last review
    2004effective

    Coverage Criteria and Evidence Considerations

    inv-01: Medically necessary indications

    Covered when ALL of the following are met (distinct groups):

    GES for chronic gastroparesis: Gastric pacing (gastric pacemaker) and gastric electrical stimulation for treatment of symptoms of nausea and vomiting from chronic gastroparesis where diagnosis is confirmed by gastric emptying scintigraphy and symptoms are refractory to medical management including dietary modification, antiemetics, and prokinetics.diagnosis confirmed by GES

    Supports replacement/revision for complications as medically necessary

    Revision/replacement: Revision or replacement of a previously approved gastric stimulator implant for complications associated with gastric pacing (eg, bowel obstruction, gastric wall perforation, infection, lead dislodgement or lead erosion into the small intestine).complication documented
    Policy Summary
    PayerAetna
    PolicyGastric Pacing / Electrical Stimulation and Gastroesophageal Per Oral Endoscopic Myotomy
    Policy CodePolicy 0678
    Change TypeNo material changes
    Effective DateFeb 6, 2004
    Last ReviewSep 25, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization and document refractory gastroparesis with objective delayed gastric emptying and prior failure of conservative therapies.
    SourceLink
    On This Page
    Coverage Criteria and Evidence ConsiderationsCoding and Diagnostic CriteriaProvider Requirements, Prior Authorization, and DocumentationBackground and ContextDefinitions and Device Descriptions
    Per-oral endoscopic myotomy for Zenker diverticulum:
    Per-oral endoscopic myotomy (POEM) is medically necessary for treatment of Zenker diverticulum.
    diagnosis K22.5
    G-POEM for severe gastroparesis: Gastric per-oral endoscopic myotomy (G-POEM) is medically necessary for members with severe gastroparesis who meet all of the following criteria: (1) diagnosis confirmed by gastric emptying study with abnormal GES defined as gastric retention >60% at 2 hours and/or >10% at 4 hours; (2) symptom duration >6 months; and (3) inadequate response to conservative treatment including dietary modification and trial of at least one prokinetic agent (domperidone, metoclopramide, or erythromycin).>60% at 2h or >10% at 4h; >6 months; ≥1 prokinetic trial

    inv-02: Experimental and investigational (Not covered)

    Considered experimental and investigational (not covered) because effectiveness has not been established:

    G-POEM other indications: G-POEM for congenital hypertrophic pyloric stenosis and all other indications except the specified severe gastroparesis criteria.
    Temporary GES: Temporary gastric electrical stimulation (tGES) for the prediction of success of permanent GES in the treatment of gastroparesis.
    GES/Gastric pacing other indications: Gastric pacing and gastric electrical stimulation for indications other than those listed as medically necessary, including as an initial treatment for gastroparesis, autonomic nervous system disorders other than gastroparesis, cyclic vomiting syndrome, diabetes mellitus without gastroparesis, other GI dysmotility disorders, and obesity; use of a second gastric electrical stimulator is also considered experimental and investigational.

    inv-03: Contexts in which invasive therapies were studied

    Clinical contexts described in the evidence where GES or G-POEM have been considered:

    Enterra candidacy (evidence context): Patients with severe nausea and vomiting occurring on average at least once daily, refractory to aggressive anti-emetic and prokinetic therapy for at least 1 year may be considered candidates for gastric neurostimulation; Enterra is approved only for diabetic and idiopathic gastroparesis as a humanitarian device.duration >= 1 year; symptoms >= daily

    From UpToDate summary and device approval statements

    G-POEM candidacy (evidence context): G-POEM/POP has been used for refractory gastroparesis after failure of conservative measures; reported series used pre-operative evaluation including upper endoscopy and gastric emptying studies.refractory to conservative therapy

    Early evidence from small case series and retrospective series

    inv-04: Evidence-based considerations for coverage

    Coverage considerations where G-POEM may be considered reasonable when ALL of the following are met (based on studies cited):

    Selection and prior therapy: Symptoms of gastroparesis refractory to conservative/medical therapy and prior endoscopic or surgical interventions as appropriate (studies included patients who had failed Botox, transpyloric stent, PEGJ, medical therapy).

    supported by multicenter case series and pooled analyses

    Objective testing: Documented delayed gastric emptying on gastric emptying scintigraphy (GES).>20% retention suggested by one study as threshold

    some authors proposed GES thresholds as predictors of response

    Symptom severity: Elevated Gastroparesis Cardinal Symptom Index (GCSI) at baseline; several studies used GCSI for inclusion and outcome assessment.GCSI >=2.0 proposed in one study

    GCSI cut-offs were evaluated as predictors of response in some series

    Procedure setting and expertise: Procedure performed by experienced endoscopists in centers with appropriate training; studies note technical demand and variability in technique.

    training and operator experience affect generalizability

    inv-05: Comparative outcome considerations

    Comparative evidence indicates:

    Longer durable response vs GES: In a propensity‑matched retrospective study, G-POEM had significantly better and longer clinical response than gastric electrical stimulation (median duration not reached for G-POEM; 25.4 months for GES) and higher 24‑month response rate (76.6% vs 53.7%).

    single retrospective matched study

    inv-06: Evidence and guideline-based considerations

    Evidence synthesis and guideline positions relevant to coverage decisions:

    General evidence summary: Multiple systematic reviews, meta-analyses, and observational series report symptomatic improvement and improved gastric emptying after G-POEM with pooled clinical response rates ~75–84% and pooled adverse event rates ~5–12%; however, much of the evidence is from uncontrolled observational studies with short- to mid-term follow-up and substantial heterogeneity.

    supported by cited systematic reviews and pooled analyses

    Randomized evidence: A prospective randomized sham-controlled trial showed G-POEM superior to sham at 6 months (treatment success 71% vs 22%), but enrollment was stopped early and results were inconclusive in some etiologic subgroups.

    supported by Martinek et al randomized trial

    Guideline and society recommendations: Society guidance (ESGE, ACG, AGA) recommends that G-POEM be considered only in carefully selected patients, performed in expert centers, and preferably within clinical trials because of limited data on effectiveness, safety, and durability.

    supported by guideline statements

    inv-07: Coverage criteria for POEM variants

    Covered when ALL of the following are met (clinical interpretation guidance based on evidence in this section):

    General: Patient has symptomatic esophageal diverticulum (eg, dysphagia, regurgitation, aspiration) documented with validated or reported symptom scores and objective diverticulum characterization (type and size).

    References: multiple series and meta-analyses reporting indications and outcomes

    Prior management: Documentation of prior appropriate conservative or less invasive interventions (as clinically indicated) or rationale for primary advanced endoscopic approach.

    Authors note evolving role vs traditional septotomy or surgery; choice often individualized

    Provider and setting: Procedure performed by clinicians with demonstrated experience in POEM/D-POEM/Z-POEM at centers capable of managing potential complications.

    Several authors recommend centralization and expertise due to procedure complexity and complication risk

    inv-08: Coverage considerations for temporary GES

    Temporary GES testing to predict permanent GES response — coverage considerations:

    tGES utility: tGES/TPGES may be considered when used to select responders for permanent GES in drug-refractory nausea/vomiting or suspected gastroparesis, with documentation of symptom monitoring during stimulation and planned interpretation of response.

    Small trials and observational series suggest predictive utility but randomized trial results are mixed and methods variable

    Trial conduct: tGES must be performed with appropriate technique (endoscopic or percutaneous lead placement), symptom logging, and objective baseline assessments to minimize carry-over and dislodgment issues.

    Trials report electrode dislodgement and insufficient wash-out as limitations; protocol details matter

    inv-09: Evidence considerations for tGES prediction of permanent GES response

    Summarized findings and limitations from trials and studies regarding use of temporary GES to predict outcomes:

    Study findings: Some uncontrolled and pilot studies (eg, Corvinus pilot: 4/6 responders) and larger case series suggest tGES may predict response to permanent GES and may be cost‑saving.

    corresponds to small pilot and observational data

    Randomized trial results: Randomized trials (eg, Abell et al) did not demonstrate statistically significant overall treatment effects; suggested reductions in vomiting were limited by design issues such as insufficient wash-out and carry-over effects.

    RCTs had methodological limitations

    Methodological limitations: Key limitations include small sample sizes (eg, n=58 in one trial), electrode dislodgement (~22%), insufficient wash‑out duration causing carry‑over effects, baseline imbalances, continuation of concomitant medications, and missing data, all of which affect predictive validity of tGES.

    These factors should be considered when interpreting tGES results

    EGG utility: Cutaneous and mucosal electrogastrogram (EGG) measures correlated with symptoms and gastric emptying and may help identify patients likely to require GES; mucosal and cutaneous measures correlated pre‑ and post‑treatment in some series.

    Shine et al and other series reported correlations

    Operational note: tGES techniques vary (trans-nasal leads, G-tube electrodes, laparoscopic temporary electrodes) and some methods are not commercially available; centers using tGES should document methods and acknowledge limitations.

    implementation dependent

    The policy explicitly states that the use of a second gastric electrical stimulator to treat persistent symptoms of chronic gastroparesis is considered experimental and investigational. This determination reflects the absence of sufficient evidence to support effectiveness for placing an additional implanted stimulator when initial therapy has failed.

    Gastric pacing and implantable gastric stimulation for obesity remain experimental. Multiple trials and assessments have not established consistent or durable benefit: randomized data (Shikora et al., 2009) showed no difference in excess weight loss between stimulation-on and control groups, and other trials and cohort studies reported inconsistent effects on gastric emptying and transient weight loss, supporting a not‑established stance for obesity indications.

    There is no standardized G-POEM technique or consensus across studies. Published series describe varied technical approaches and inclusion criteria, producing heterogeneous methods and patient selection that limit generalizability to centers without experienced endoscopists.

    G-POEM should not be used as first-line therapy. Society guidance and clinical reviews recommend reserving G-POEM for carefully selected patients and performing the procedure in tertiary or expert centers, ideally within clinical trials or structured programs given limited long-term data.

    Procedures performed for asymptomatic diverticula or solely for surveillance of a low‑risk remnant diverticulum are not supported by the outcome studies cited. Interventional treatment is indicated for symptomatic diverticula (dysphagia, regurgitation, aspiration), so procedures done only for surveillance or on asymptomatic lesions may be considered not covered.

    Techniques for temporary gastric electrical stimulation (tGES) vary and are not all commercially available. The policy notes that some described methods (e.g., endoscopic mucosal leads or G-tube electrodes) lack commercial availability, which may limit practical use and programmatic adoption.

    This Clinical Policy Bulletin provides a partial description of plan benefits and coverage positions. It does not itself guarantee coverage—administrative plan or contract provisions govern actual benefits and prior authorization requirements should be confirmed with the member's plan.

    The policy indicates that GES or gastric pacing is considered investigational for indications beyond the listed medically necessary uses, including treatment of obesity, autonomic nervous system disorders other than gastroparesis, cyclic vomiting syndrome, and diabetes without objective gastroparesis. These uses are not supported by the evidence summarized in the policy.

    Implantable gastric stimulation for morbid obesity is not supported by the totality of evidence. A randomized trial (Shikora et al.) found no significant difference in excess weight loss between stimulation-on and control groups, and subsequent studies have not demonstrated consistent, sustained benefit.

    The body of evidence for G-POEM and GES is largely composed of small, often retrospective series with relatively short follow-up. As a result, durability of benefit and optimal patient selection remain unconfirmed, and routine use without documented refractory disease and objective testing is not supported.

    Randomized, sham‑controlled studies are limited and long-term follow-up data are lacking. Guideline statements emphasize these limitations, which temper the strength of recommendations for routine use of G-POEM outside selected, expert settings.

    POEM variants (D-POEM, Z-POEM) performed without documentation of symptom burden or when the treating center or operator cannot demonstrate appropriate expertise may be considered not medically necessary. Comparative randomized data and long-term outcome studies are limited, increasing the risk of insufficient justification for these procedures in non‑expert settings.

    Routine use of temporary GES to predict response to permanent implantation is not supported because trial results are inconsistent and study methodology varies. Limitations across studies include small sample sizes, high electrode dislodgment rates, insufficient wash-out and carry-over effects, and mixed randomized trial results; these methodological issues reduce confidence in routine adoption of tGES as a definitive selection tool.

    Coding and Diagnostic Criteria

    CPT codes covered if selection criteria are metCPTCovered
    43180Esophagoscopy, rigid, transoral with diverticulectomy of hypopharynx or cervical esophagus (eg, Zenker's diverticulum), with cricopharyngeal myotomy, includes use of telescope or operating microscope and repair, when performed.
    43497Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM]).
    43647Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
    43648Revision or removal of gastric neurostimulator electrodes, antrum.
    43881Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
    43882Revision or removal of gastric neurostimulator electrodes, antrum, open.
    64590Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling.
    64595Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver.
    95980Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming.
    95981Electronic analysis subsequent, without reprogramming.
    1–10 of 11
    1/2
    CPT codes not covered / no specific codemixedNot Covered
    Diverticular peroral endoscopic myotomy (D-POEM)Not specifically coded here
    temporary gastric electrical stimulation (GES)no specific code
    Related diagnostic CPT codesCPT
    78264Gastric emptying imaging study (eg, solid, liquid, or both).
    78265Gastric emptying imaging study; with small bowel transit.
    78266Gastric emptying imaging study; with small bowel and colon transit, multiple days.
    HCPCS supply codesHCPCSCovered
    C1767Generator, neurostimulator (implantable), non-rechargeable.
    C1778Lead, neurostimulator (implantable).
    L8679Implantable neurostimulator pulse generator, any type.
    L8680Implantable neurostimulator electrode, each.
    L8688Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    K31.84Gastroparesis.
    E10.43Diabetic gastroparesis.
    K22.5Diverticulum of esophagus, acquired.
    ICD-10 codes not covered for listed indications (not all-inclusive)ICD-10Not Covered
    E08.00 - E13.9 (ranges listed)Diabetes mellitus codes listed as not covered for certain indications.
    E66.01 - E66.9 (ranges listed)Obesity and morbid obesity codes.
    F50.81 - F50.89Other eating disorders [psychogenic cyclic vomiting].
    G43.A0 - G43.A1Cyclical vomiting codes.
    G90.01 - G90.ADisorders of autonomic nervous system.
    K30Functional dyspepsia.
    Q40.0Congenital hypertrophic pyloric stenosis.
    No explicit codes in this excerptmixed
    No codes listed
    Gastric emptying scintigraphy abnormal retention thresholds
    GES abnormal retention thresholds>60% gastric retention at 2 hours and/or >10% gastric retention at 4 hours on gastric emptying scintigraphy (GES)
    Context of useThresholds used to confirm diagnosis of gastroparesis when considering G-POEM per policy medical necessity criteria
    Measurement timingRetention measured at 2-hour and 4-hour time points after meal ingestion on solid-phase GES
    GCSI — proposed selection threshold
    Proposed GCSI selection thresholdGastroparesis Cardinal Symptom Index (GCSI) ≥ 2.0 proposed as a selection threshold in one retrospective study (n = 40)
    Role in studiesGCSI used in multiple studies for baseline assessment and outcome measurement of gastroparesis interventions
    Predictive analysesUnivariate analyses in some series showed association of GCSI with outcomes though findings were not always confirmed in multivariate models
    Gastric retention on GES — proposed selection threshold
    Proposed GES retention threshold>20% gastric retention on GES proposed as a selection threshold in one retrospective study
    Study contextThe >20% retention threshold was suggested alongside a proposed GCSI ≥2.0 in a small (n = 40) retrospective series
    Policy vs study thresholdsPolicy medical-necessity criteria use higher GES thresholds (>60% at 2h or >10% at 4h) for G-POEM candidacy; the >20% figure was a proposed study threshold

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization for implants, revisions, removals, and related billing codes

    Prior authorization is required for implantation, revision, removal, and related CPT/HCPCS codes when selection criteria in the policy are being used to determine medical necessity.

    • Applies to listed CPT codes for implantation, revision, removal, and pulse generator programming/analysis (see coding section).
    Prior Authorization

    Prior authorization must document indication for GES/IGS (humanitarian/exempt uses only)

    Authorization for implantation of investigational or humanitarian-exemption gastric stimulation devices should include documentation of the indication (for Enterra: diabetic or idiopathic gastroparesis) and prior failed conservative therapy.

    • Enterra is approved as a humanitarian exemption device only for diabetic and idiopathic gastroparesis; obesity indications lack consistent benefit.
    Prior Authorization

    Document refractory gastroparesis and objective delayed gastric emptying for prior authorization

    Prior authorization requests should document refractory gastroparesis with objective delayed gastric emptying on GES and prior failure of conservative therapies including dietary modification and antiemetics/prokinetics.

    • G-POEM medically necessary criteria require GES showing >60% retention at 2 hours and/or >10% at 4 hours, symptom duration >6 months, and inadequate response to conservative treatment including a trial of at least one prokinetic.
    Prior Authorization

    Document expert‑center selection and prior therapies for advanced procedures

    Prior authorization should show that patients selected for procedures such as G-POEM are carefully chosen and that the procedure will be performed at tertiary/expert centers after failure of prior treatments.

    • Society guidance recommends G-POEM be performed in expert centers only, preferably in the context of clinical trials.
    Prior Authorization

    Submit symptom severity, prior therapies, diverticulum details, and center expertise for POEM variant authorization

    For POEM variants, prior authorization should include symptomatic severity, prior therapies tried, diverticulum characteristics (type/size), and evidence of provider/center experience.

    • Documentation should include validated symptom scores (e.g., Eckardt) and details on prior conservative or endoscopic/surgical interventions.
    Prior Authorization

    Provide documentation of temporary GES predictive testing when used to justify permanent GES

    If a center uses temporary stimulating electrodes (tGES) to select responders, prior authorization may require submission of documentation of that predictive testing and its results to justify permanent implantation.

    • Describe the tGES method used (endoscopic or percutaneous leads), symptom monitoring during stimulation, and interpretation of response.
    Note

    Confirm plan coverage and prior authorization requirements with the payer

    Verify plan-specific coverage and prior authorization requirements with the member's plan because Clinical Policy Bulletins do not guarantee coverage and plan provisions govern.

    • Providers are responsible for confirming benefits and prior authorization rules with the payer before proceeding.
    Step Therapy

    Document failure of conservative therapy including dietary changes and ≥1 prokinetic before G-POEM

    Prior to G-POEM, members must have failed conservative treatments including dietary modification and a trial of at least one prokinetic agent.

    • Acceptable prokinetics listed include domperidone, metoclopramide, or erythromycin per the policy's G-POEM criteria.
    Step Therapy

    Ensure conservative/prokinetic/antiemetic therapy has failed before invasive interventions

    Candidates for invasive interventions (GES or G-POEM) should have refractory symptoms after conservative/prokinetic/antiemetic therapy; prior authorization should reflect this treatment history.

    • Many series included patients who had failed Botox, transpyloric stent, PEGJ, or medical therapy prior to advanced procedures.
    Step Therapy

    Position G-POEM after conservative and prior endoscopic/surgical interventions in treatment sequencing

    G-POEM is an organ‑sparing option considered after failure of conservative measures and may be considered relative to prior interventions such as endoscopic dilation, Botox, stenting, or surgical pyloroplasty.

    • Document prior interventions and rationale for choosing G-POEM as the next step in therapy.
    Note

    Consider prior pyloric-targeted therapies (Botox, prior GES) when evaluating candidates

    When evaluating candidates, consider prior pyloric‑targeted therapies (e.g., Botox, prior gastric stimulator) because published series often report these prior treatments and they may predict response to G-POEM.

    • Meta-regression identified prior treatment with Botox and gastric stimulator as potential predictors of clinical success with G-POEM.
    Step Therapy

    Sequence therapy: consider established septotomy/surgical options before advanced tunneling techniques

    Consider less invasive established endoscopic septotomy or surgical options when appropriate before advanced tunneling techniques like Z-POEM or D-POEM; document reasons if proceeding directly to advanced techniques.

    • Authors note randomized and comparative studies are lacking; procedure choice should be individualized and justified.
    Step Therapy

    If tGES used as a selection step, submit detailed tGES method and response documentation

    Temporary GES (via G‑tube or endoscopic mucosal leads) has been used by some centers as a selection step to identify likely responders before permanent implantation; documentation of tGES procedure and response should be submitted if relied on for decision-making.

    • tGES techniques vary (trans-nasal leads, G-tube electrodes, laparoscopic temporary electrodes) and some are not commercially available; document method and limitations.
    Note
    Documentation Required

    Include GES confirmation, prior conservative management, and prokinetic trials in documentation

    Documentation must demonstrate diagnosis confirmation by gastric emptying study when required, prior conservative management and trials of prokinetic agents, and reason for revision/replacement if applicable.

    • For G-POEM, include GES results meeting policy thresholds (>60% at 2 hours and/or >10% at 4 hours), symptom duration, and trial of at least one prokinetic.
    Documentation Required

    Submit pre-operative evaluation (upper endoscopy, GES; pH/manometry if indicated) for G-POEM/POP

    Pre-operative work‑up for G-POEM/POP in reported series included upper endoscopy and gastric emptying study; pH study and esophageal manometry were performed when concomitant fundoplication was considered.

    • Ensure pre-op testing and rationale for additional studies are documented in the prior authorization record.
    Documentation Required

    Provide baseline GCSI and GES results as part of clinical assessment documentation

    Baseline assessments reported in studies include the Gastroparesis Cardinal Symptom Index (GCSI) and gastric emptying scintigraphy (GES); include these measures in authorization and follow-up documentation.

    • Some authors proposed selection thresholds using GCSI and GES; include baseline scores and objective test results.
    Documentation Required

    Document baseline and follow‑up GCSI and 4‑hour GES results to show response

    Documentation should include baseline and follow‑up GCSI scores and gastric emptying scintigraphy results (4‑hour retention) to demonstrate clinical response as used in cited studies.

    • Studies used GCSI change and 4‑hour GES retention to define treatment success; include these data in outcomes reporting.
    Documentation Required

    Provide indication, prior treatments, diverticulum characteristics, and center experience for POEM variants

    For POEM variants treating diverticula, include indication (symptomatic diverticulum with dysphagia/regurgitation/aspiration), prior conservative or alternative therapies, diverticulum type and size, and provider/center experience.

    • Include validated symptom scores (e.g., Eckardt, Kothari‑Haber) and documentation of prior treatments or rationale for advanced endoscopic approach.
    Documentation Required

    Submit baseline/post‑tGES EGG measures, GETs, and standardized symptom scores when using tGES

    When tGES is used, documentation should include baseline and post‑tGES electrogastrogram (EGG) measures (frequency, amplitude, propagation), gastric emptying tests, and standardized patient‑reported outcome scores to support interpretation.

    • EGG measures correlated with symptoms and GET results in studies and may help identify patients likely to require GES.
    Note

    Providers must verify member coverage and prior authorization rules with the plan

    Verify benefits and prior authorization requirements with the member's plan; Clinical Policy Bulletins are a partial description of plan benefits and do not constitute a guarantee of coverage.

    • Providers are responsible for confirming plan‑specific provisions before scheduling procedures.
    Denial Risk

    Denial risk: investigational procedures may be denied without evidence meeting policy criteria

    Procedures considered experimental/investigational—such as G-POEM for indications other than the policy-specified severe gastroparesis criteria, temporary GES to predict permanent GES success, or use of a second gastric electrical stimulator—may be denied as not established.

    • Temporary GES for prediction of success is explicitly listed as experimental and investigational in the policy.
    Denial Risk

    Denial risk: humanitarian‑exemption device use outside approved indications may not be covered

    Devices approved under a humanitarian exemption (Enterra) are limited to diabetic and idiopathic gastroparesis; use outside these indications may be denied.

    • UpToDate and policy state Enterra is approved only for diabetic and idiopathic gastroparesis.
    Denial Risk

    Potential denial trigger: lack of documentation meeting proposed GCSI and GES thresholds (GCSI ≥2.0; retention >20%)

    One study proposed selection thresholds of GCSI ≥ 2.0 and gastric retention >20%; absence of documentation showing patients meet such proposed criteria may prompt questions or denial.

    • This proposed threshold came from a relatively small retrospective study and is not the policy's primary G-POEM threshold.
    Denial Risk

    Denial risk: procedures performed outside expert centers or trial contexts may be restricted

    Guidelines recommend G-POEM be considered only in carefully selected patients and performed in expert centers, preferably in clinical trials; lack of expert‑center performance or trial context may increase denial risk.

    • ESGE and AGA/ACG guidance emphasize performance in tertiary centers with multidisciplinary expertise.
    Denial Risk

    Denial risk: limited evidence or lack of center expertise for newer POEM variants may lead to denial

    Procedures lacking randomized trial evidence, long‑term outcomes, or performed outside centers with appropriate expertise (e.g., D‑POEM, Z‑POEM) carry higher risk for coverage denial when medical necessity is not clearly documented.

    • Policy notes limited randomized data and variable long‑term outcomes as reasons for restricting routine coverage.
    Denial Risk

    Denial risk: inadequate tGES technique or documentation (electrode dislodgement, insufficient wash‑out) may invalidate results

    tGES testing has validity risks—studies reported high electrode dislodgement rates and small sample sizes; inadequate technique, dislodgement, insufficient wash‑out, or incomplete documentation may lead to questioning of test validity and denial.

    • One trial reported electrode dislodgement in 22% of patients and cited potential carry‑over effects due to insufficient wash‑out.
    Note

    Coverage contingent on plan benefits—verify contract terms before proceeding

    Coverage is contingent on the member's plan benefits and contract language; Clinical Policy Bulletins do not guarantee coverage and administrative or contractual limitations may apply.

    • Confirm plan terms and prior authorization requirements before scheduling treatment.

    Background and Context

    Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying and symptoms such as nausea, vomiting, bloating and consequences for nutrition. Causes include diabetic and idiopathic etiologies and the condition is the clinical context for consideration of GES and G-POEM.

    Definitions and Device Descriptions

    Enterra Therapy System (GES)
    DefinitionEnterra Therapy System: an implanted high-frequency (12 cycles/min), low-energy gastric electrical stimulation (GES) system
    Regulatory statusEnterra Therapy II is the only GES system approved for marketing in the U.S. under a Humanitarian Device Exemption (HDE)
    Stimulation characteristicsDelivers high-frequency, low-energy stimulation distinct from low-frequency gastric pacing
    Gastric pacing (gastric pacemaker)
    DefinitionGastric pacing (gastric pacemaker): system using pacing wires attached to the stomach with an external electrical device to provide low-frequency, high-energy stimulation to entrain stomach rhythm (~3 cycles/min)
    Practical considerationsGastric pacemaker systems are cumbersome for chronic use due to external leads
    Enterra Therapy — regulatory indication
    Regulatory descriptionEnterra Therapy (gastric electrical neurostimulator) is approved in the U.S. as a humanitarian exemption device for diabetic and idiopathic gastroparesis
    Indicated populationApproval limited to diabetic and idiopathic gastroparesis per device labeling and reviews
    G-POEM / POP — procedure description
    Procedure descriptionPer-oral endoscopic pyloromyotomy (G-POEM/POP): endoscopic incisionless pyloroplasty performed via submucosal tunneling to cut the pyloric muscle (pyloromyotomy)
    Intended useProposed as a minimally invasive treatment for refractory gastroparesis after failure of conservative therapy
    Pre-operative evaluationReported series included upper endoscopy and gastric emptying study; pH manometry when indicated
    Closed-loop gastric electrical stimulation (CLGES)
    DefinitionClosed-loop gastric electrical stimulation (CLGES): a system pairing sensor-based behavior monitoring with electrical stimulation to modify eating behavior and weight outcomes
    Clinical contextStudied as an obesity treatment with implanted sensors and stimulation; small randomized multi-center trials reported up to 24-month follow-up data
    G-POEM (gastric per-oral endoscopic myotomy)
    DefinitionG-POEM (gastric per-oral endoscopic myotomy): endoscopic submucosal tunneling and pyloromyotomy performed as an incisionless pyloroplasty to improve gastric emptying and symptoms in refractory gastroparesis
    SynonymsAlso referred to as per-oral pyloromyotomy (POP) in some series
    GCSI (Gastroparesis Cardinal Symptom Index)
    DefinitionGCSI (Gastroparesis Cardinal Symptom Index): a validated patient-reported symptom score used to quantify severity of gastroparesis symptoms and assess response to interventions
    Use in studiesEmployed as baseline assessment and outcome measure in multiple G-POEM and GES studies
    GES (gastric emptying scintigraphy)
    DefinitionGES (gastric emptying scintigraphy): an objective nuclear medicine test measuring gastric emptying used to document delayed gastric emptying and assess response to therapy
    Role in coveragePolicy requires GES confirmation of delayed emptying (specified retention thresholds) for some procedures such as G-POEM
    G-POEM — endoscopic pyloroplasty definition
    DefinitionG-POEM: an endoscopic equivalent of surgical pyloroplasty performed via submucosal tunneling to perform pyloromyotomy
    Clinical evidenceDescribed in case series, multicenter reports, and systematic reviews as an emerging treatment for refractory gastroparesis
    D-POEM — definition
    DefinitionD-POEM: diverticular peroral endoscopic myotomy — application of submucosal endoscopic myotomy techniques to treat esophageal diverticula (eg, Zenker's, epiphrenic)
    Clinical contextUsed for symptomatic esophageal diverticula with reported technical and clinical success in small series
    D-POEM / Z-POEM — definitions
    DefinitionsD-POEM / Z-POEM: per-oral endoscopic myotomy techniques adapted for diverticular and Zenker's diverticulum management via submucosal tunneling septotomy
    Evidence notePublished multicenter and prospective series report technical success and symptom improvement but long-term outcomes remain under study
    MIMI — technique definition
    DefinitionMIMI: mucosal incision and muscular interruption — a modified Z-POEM technique where the submucosal tunnel is made directly over the cricopharyngeus
    Clinical cautionMay increase perforation risk in small Zenker's diverticula or with cricopharyngeal bar; larger studies needed
    Temporary GES — definition and considerations
    DefinitionTemporary GES (tGES/TPGES): short-term placement of stimulating electrodes (via G-tube, endoscopic mucosal leads, or percutaneous electrodes) connected to an external stimulator to assess symptomatic response prior to possible permanent implantation
    Method variabilityTechniques include endoscopic mucosal leads, percutaneous implants, and laparoscopic temporary electrodes; methods and availability vary by center
    LimitationsStudies report electrode dislodgement, small sample sizes, and methodological issues limiting predictive validity
    Gastroparesis — definition
    DefinitionGastroparesis: delayed gastric emptying without mechanical obstruction (etiologies include idiopathic, diabetic, post-surgical, and others)
    Clinical featuresPresents with nausea, vomiting, bloating, early satiety, weight loss, and potential nutritional compromise in severe cases
    Electrogastrogram (EGG)
    DefinitionElectrogastrogram (EGG): noninvasive cutaneous recordings of gastric electrical activity (frequency, amplitude, propagation) that correlate with mucosal electrograms and gastric emptying measures
    Clinical utilityShort EGG recordings have been shown to correlate with symptoms and GETs and may help identify patients for GES
    Temporary GES (tGES) — short-term stimulation
    DefinitionTemporary GES (tGES): short-term placement of stimulating electrodes connected to an external stimulator to assess symptomatic response prior to possible permanent implantation
    Placement routesElectrodes may be placed via G-tube, endoscopic mucosal leads (nasogastric-style), percutaneous or laparoscopic approaches
    G-POEM / per-oral endoscopic pyloromyotomy
    Equivalent descriptionG-POEM / per-oral endoscopic pyloromyotomy: endoscopic pyloromyotomy via submucosal tunneling to treat refractory gastroparesis; described across systematic reviews and multicenter series
    Evidence sourcesReferenced in UpToDate, systematic reviews, multicenter series, and randomized pilot data
    D-POEM / Z-POEM — definitions and context
    DefinitionD-POEM / Z-POEM: per-oral endoscopic myotomy techniques adapted for management of esophageal diverticula and Zenker's diverticulum
    EvidenceSupported by multicenter studies, prospective series, and systematic reviews describing technical feasibility and symptomatic improvement